Mitoxantrone With or Without Docetaxel in Treating Women With Metastatic Breast Cancer
This study has been completed.
Arbeitsgemeinschaft fur Internistische Onkologie
Information provided by:
National Cancer Institute (NCI)
First received: November 1, 1999
Last updated: August 1, 2013
Last verified: April 2001
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Study Completion Date:||November 2002|
|Estimated Primary Completion Date:||No date given|
Heidemann E, Stoeger H, Souchon R, Hirschmann WD, Bodenstein H, Oberhoff C, Fischer JT, Schulze M, Clemens M, Andreesen R, Mahlke M, Konig M, Scharl A, Fehnle K, Kaufmann M. Is first-line single-agent mitoxantrone in the treatment of high-risk metastatic breast cancer patients as effective as combination chemotherapy? No difference in survival but higher quality of life were found in a multicenter randomized trial. Ann Oncol. 2002 Nov;13(11):1717-29.